About Bioenvision
Bioenvision is a company based in New York (United States) founded in 1996 was acquired by Genzyme in May 2007. Bioenvision has raised $7.4 million across 1 funding round from investors including Genzyme. Bioenvision operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter New York, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Bioenvision
Bioenvision has successfully raised a total of $7.4M through 1 strategic funding round. The most recent funding activity was a Series A round of $7.4 million completed in May 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Bioenvision
Bioenvision has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Genzyme.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biopharmaceutical products for rare genetic diseases are developed and supplied.
|
Locked | Locked | Locked |
Investor details for Bioenvision
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Bioenvision
Investment portfolio details for Bioenvision
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Bioenvision
Detailed financials for Bioenvision
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bioenvision Comparisons
Peer comparison for Bioenvision
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Bioenvision
Bioenvision operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Bioenvision
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bioenvision
Complete news archive for Bioenvision
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bioenvision
Bioenvision was founded in 1996 and raised its 1st funding round 11 years after it was founded.
Bioenvision is headquartered in New York, United States. It is registered at New York, New York, United States.
Bioenvision is a funded company, having raised a total of $7.4M across 1 funding round to date.
Bioenvision (Previously Ascot Group) engages in the acquisition, development, and marketing of compounds and technologies primarily for the treatment of cancer. Its lead products include Evoltra (clofarabine) which has marketing approval in both the European Union and the United States for the treatment of pediatric relapsed or refractory acute lymphoblastic leukemia and Modrenal (trilostane), which has marketing approval in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy. It was acquired by Genzyme Corporation in Oct, 2007.
Bioenvision's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Bioenvision has 1 investor. Key investors include Genzyme.